submit to the journals

Videos

As well as peer-reviewed journals, touchONCOLOGY also provide video interviews, procedures and general updates on the latest trends within the area, as well as featuring carefully selected video from our partners.
András Illés, ESMO 2018 – A New Biosimilar for the Treatment of Chemotherapy-induced Neutropenia
In an expert interview at ESMO 2018, Dr András Illés discusses the current research behind RGB-02, a biosimilar pegfilgrastim for the treatment of chemotherapy-induced neutropenia. Biosimilars are subjected to rigorous clinical trials to ensure equivalence to the originator drug in terms of safety...
Maria Domenica Cappellini, ASH 2018 – Gaucher Disease for the Haematologist
Professor Maria Domenica Cappellini joined touchONCOLOGY at ASH 2018 to discuss haematologists' approach to Gaucher disease, focusing on the diagnosis and follow-up of this rare genetic condition. Professor Cappellini outlines the current issue of slow diagnosis times, and emphasises the importance...
Robin Foà, ASH 2018 – Developments in the Treatment of Haematological Malignancies
In this interview, filmed at ASH 2018, Dr Robin Foà talks to touchONCOLOGY about recent developments in the treatment of haematological malignancies, namely the identification of new genetic abnormalities, the increase in chemotherapy-free treatments, and the use of molecular technologies to...
Constantine Mitsiades, ASH 2018 – Latest Developments in the Treatment of Multiple Myeloma
In this interview, filmed at ASH 2018, Dr Constantine Mitsiades talks to touchONCOLOGY about the current and future treatment landscape of multiple myeloma. One of the most significant recent developments in the treatment of multiple myeloma, has been monoclonal antibodies (mAbs), particularly...
Mohamad Mohty, ASH 2018 – Epstein-Barr Virus and Cytotoxic T Lymphocyte Therapy
At ASH 2018 editorial board member, Dr Mohamad Mohty, discusses Epstein-Barr virus associated post-transplant lymphoproliferative disorder (EBVPTLD) and developments in its treatment. EBVPTLD is a serious, life-threatening condition which can occur as a result allogeneic stem cell transplantation...
Wadie Bahou, ASH 2018 – Platelets and Platelet-related Biomarkers in Tumor Biology and Metastasis
Dr Wadie Bahou answers our questions about the role of platelets in tumor biology and metastasis and the significance and usefulness of platelet-related biomarkers in the detection and monitoring of hematologic and oncologic diseases. Questions: 1. What is the role of platelets in tumor biology...
Austin Kulasekararaj, ASH 2018 – Treatments for Paroxysmal Nocturnal Hemoglobinuria
In this interview filmed at ASH 2018, Dr Austin Kulasekararaj discusses the phase III non-inferiority study investigating ravulizumab (ALXN1210) versus eculizumab in adult patients with paroxysmal nocturnal hemoglobinuria in patients currently treated with eculizumab. He then goes on to discuss how...
Morie A Gertz, ASH 2018 – Hereditary TTR Amyloidosis and the NEURO-TTR Study
We spoke to Professor Morie Getz at ASH 2018 about the current unmet needs in treatment of hereditary TTR amyloidosis, antisense technology, inotersen and the NEURO-TTR study. Questions: 1. What is hereditary TTR amyloidosis and what are the unmet needs in its treatment? (0:10) 2. Could you...
Nicolaus Kröger, ASH 2018 - Treatment of Myelodysplastic Syndrome in Elderly Patients
Professor Nicolaus Kröger spoke to us at ASH 2018 about the major unmet needs in the treatment of myelodysplastic syndrome in elderly patients, and his phase III study comparing 5-azacytidine induction followed by allogeneic stem cell transplantation versus continuous 5-azacytidine according to...
Dirk Schadendorf, ESMO 2018 – Encorafenib plus Binimetinib for BRAF-mutant Metastatic Melanoma
In this interview, filmed at ESMO 2018, Professor Schadendorf discusses the use of encorafenib plus binimetinib for BRAF-mutant metastatic melanoma. Questions: 1. Could you tell us a little about the efficacy and safety findings of the COLUMBUS study that have led to the recent European...
Daniel A Vorobiof, ESMO 2018 – Prevalence of Cancer-related Fatigue
Dr Daniel A Vorobiof, ​Chief Medical Officer at Belong.Life, New York, NY, US, provides an overview of the findings of his study on the impact of cancer-related fatigue on patients and caregivers, and options of management and prevention.​ Belong.Life is the world’s largest professional social...
Do-Youn Oh, ESMO 2018 – M7824 for the Treatment of Biliary Tract Cancer
In this interview, filmed at ESMO 2018, Dr Do-Youn Oh highlights the importance of these results for biliary tract cancer, and where she thinks future research could lead. Questions: 1. What was the background and rationale behind the phase 1 study investigating M7824 in biliary tract cancer...
Marc Peeters, ESMO 2018 – Using Biomarkers to Guide Treatment in Colorectal Cancer
In this interview at ESMO 2018, Marc Peeters talks to touchONCOLOGY about colorectal cancer tumour location and biomarkers. He explains that left-sided cancers have a better prognosis and suggests some possible reasons for this. Dr Peeters also discusses how the use of biomarkers has developed in...
Eva C Winkler, ESMO 2018 – Financial Toxicity in German Cancer Patients: How Does a Chronic Disease Impact the Economic Situation?
There is a lack of consistency regarding what constitutes as financial toxicity and how to measure it in patients who have cancer. At this year’s ESMO, we met up with Dr Eva Winkler to learn more about this under-researched topic. As patients with cancer live longer, their financial burden...
Raffaele Califano, ESMO 2018 – Mechanisms of Resistance in Non-small Cell Lung Cancer
In this interview, at ESMO 2018, Dr Raffaele Califano talks to touchONCOLOGY about epidermal growth factor receptor (EGFR) expression in non-small cell lung cancer (NSCLC). He explains the importance of detecting EGFR activity prior to treatment in order to treat the patient effectively. Dr...

Out Now